Af­ter ran­corous threats and a clin­i­cal hold, Ap­plied Ther­a­peu­tics is set to re­sume pe­di­atric galac­tosemia study

Af­ter an anony­mous re­port raised red flags over Ap­plied Ther­a­peu­tics’ in­tegri­ty in Ju­ly, say­ing the com­pa­ny “cher­ry picked” da­ta and os­ten­si­bly prompt­ing a short at­tack, the biotech ac­cused the au­thors of the re­port of fraud and threat­ened le­gal ac­tion. Then, a month lat­er, the FDA in­di­cat­ed it al­so had con­cerns over its lead galac­tosemia pro­gram, slap­ping a clin­i­cal hold on a study test­ing their can­di­date in chil­dren.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.